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INTRODUCTION
The ovary is a common site of metastases from other pri-
mary malignancies, and 5-30% of ovarian cancers are meta-
static malignancies. The most common primary origins are
the breast, colon, and stomach (1). The incidence rate of
metastatic ovarian cancer appears to be somewhat higher in
Asia compared to Western countries (2-7). The prevalence
of metastatic ovarian tumors appears to be associated with
the incidence rates and spread patterns of primary malig-
nancies.
When gynecologists are confronted with tumors metasta-
sized to the ovaries, the pre- and intraoperative distinction
of the tumors from primary ovarian malignancies is often
difficult. A history of malignancy can provide a useful clue
for diagnosing metastatic ovarian tumor, but symptoms due
to the tumor can mask the primary neoplasm. Occasionally,
metastatic ovarian tumors mimic a primary ovarian neoplasm
morphologically and clinically. Furthermore, the radiologi-
cal features of metastatic ovarian cancer show considerable
variability (8-11).
Because metastatic ovarian cancer is not a target of typical
chemo- and radiotherapy, there are few clinical reports on
tumor management or prognostic factors. Cytoreductive sur-
gery in metastatic ovarian cancer may be beneficial for the
initial diagnosis or symptom relief, but the survival benefit
of surgery remains controversial (3, 5, 12-16). In the present
study, we evaluated the prevalence of metastatic ovarian can-
cer and preoperative characteristics, including diagnostic
imaging findings, origin of primary malignancy, age of pa-
tient, mass size, bilaterality, and serum markers. We also ana-
lyzed the clinical effects of cytoreductive surgery in treating
metastatic ovarian cancer.
MATERIALS AND METHODS
We identified patients from the records of the Department
of Pathology at the Catholic University of Korea, retrieved
through searches of the pathology report database and the
medical informatics cancer registry at the Catholic Medical
Center. The records of 821 patients with ovarian malignan-
cies between 1 January 1996 and 31 December 2006 were
screened, according to International Classification of Disease
(ICD)-10 codes. For inclusion in this study, ovarian metas-
tasis confirmed by histological and immunologic stains (i.e.,
cytokeratins 7 or 20) and pathological or clinical confirma-
tion of the primary tumor were required. We included data
from patients with metastatic tumor from other genital tract
(i.e., uterus, cervix and fallopian tube, only except ovary). Two
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Clinical Characteristics of Metastatic Tumors to the Ovaries 
Approximately 5-30% of the ovarian cancers are metastatic malignancies. The
prevalence of metastatic ovarian tumors varies with the incidence rates and spread
patterns of primary malignancies. We evaluated the prevalence, pre- and postop-
erative characteristics of metastatic ovarian cancer in Korean women. We reviewed
the records for 821 ovarian malignancies with pathological consultation from 1996-
2006 and recorded patient demographical, radiological, histopathological, and sur-
vival data. The study included 112 cases of histologically confirmed metastatic ovari-
an cancer. Metastatic ovarian cancer accounted for 13.6% of all ovarian malignan-
cy, primarily arising from the gastrointestinal tract. The preoperative detection rate
with imaging was 75%, and none of the radiological or serological features were
useful for differential diagnosis. In multivariate analysis for prognostic variables, the
only significant factor was the primary tumor site (p=0.004). Furthermore, exten-
sive resection increased survival for some patients. The differential diagnosis of
metastatic ovarian cancer can be problematic, so multiple diagnostic approaches
are necessary. The extent of cytoreductive surgery for this type of tumor must be
decided on a case-by-case basis. 
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cases of primary ovarian cancer and one case with uncertain
information were excluded based on the advice of a participat-
ing pathologist (A.W.L.). A total of 112 patients with his-
tologically confirmed metastatic ovarian cancer were selected.
We recorded patient information, including age, meno-
pause status, origin of the primary malignancy, the sequence
and interval of diagnosing the primary and secondary tumors,
cell type, radiology findings, preoperative serum cancer anti-
gen (CA)-125 concentration, ascites, mass size, bilaterality,
cytoreductive surgery results, and survival. Not all clinical
data were available for all cases. Therefore, we calculated per-
centages based on the number of cases for which appropriate
data were available. Surgical treatment was categorized as (1)
extensive (e.g., optimal mass removal by primary tumor resec-
tion plus total hysterectomy with unilateral or bilateral salp-
ingo-oophorectomy and/or pelvic lymphadenectomy, omen-
tectomy, or other excisional mass removal procedures) or (2)
minimal (e.g., palliative debulking, including incomplete
removal of primary tumor and salpingo-oophorectomy, wedge
resection or biopsy of ovarian masses). Surgery was defined as
optimal when the largest residual tumor mass was <2 cm.
Statistical analyses included ANOVA, Fisher’s exact test,
Wilcoxon rank sum test and Kruskal-Wallis test as appro-
priate. We computed survival curves using the Kaplan-Meier’s
method, and we analyzed the prognostic variables with the
log-rank test (univariate) and the Cox proportional hazards
model (multivariate). Results were considered statistically
significant if p<0.05. The study was approved by the appro-
priate institutional review board at the Catholic Medical
Center.
RESULTS
Metastatic ovarian malignancy accounted for 112 (13.6%)
of the 821 ovarian malignancies. More than 70% of those
were metastases from the gastrointestinal tract. Colorectal
cancer was the most common primary tumor followed by
stomach cancer. Patient characteristics are summarized in
Table 1. The mean age of patients was 46.8±11.0 yr, and
39 (34.8%) of them were postmenopausal. Primary malig-
nancies were detected first in 48 (42.9%) patients and simul-
taneously with ovarian metastases in 61 (54.5%) patients.
One hundred eight (94%) of the primary malignancies were
classified as adenocarcinomas. Adjuvant therapy (postopera-
tive chemotherapy±radiotherapy) was done in most of pa-
tients (98.2%). 
The number of patients with metastatic ovarian cancers
that did not originate in the gastrointestinal or gynecologic
organs was relatively small, and further classification of data
was required for effective statistical analyses. Therefore, we
re-categorized the data into four subgroups, according to
primary origin: 1) colorectal cancer, 2) stomach cancer, 3)
gynecologic cancer, and 4) others sites, including gallblad-
der, pancreas, breast, lung, lymphoma, and unknown origin.
Preoperative findings classified by those subgroups are sum-
marized in Table 2. Eighty-four (75%) cases were preopera-
tively diagnosed by ultrasonography, computed tomogra-
phy, or magnetic resonance imaging. The mean size of the
largest masses was 9.7±5.5 cm, and 54.5% of the cases had
bilateral ovarian involvement. There were no statistically sig-
nificant differences in the largest mass size or bilateral ovari-
an involvement among the subgroups. We considered pre-
Total
(n=112)
Lympho-
ma (n=2)
Cervix
(n=1)
Lung
(n=2)
Breast
(n=2) 
Appendix
(n=2)
Gallbladder
(n=4) 
Unknown
(n=9)
Endometri-
um (n=10)
Stomach
(n=34)
Colorectal
(n=46)
Age (yr, mean±SD) 46.8±11.0 48.7±11.0 43.6±10.2 45.8±5.8 51.1±13.4 53.8±9.5 65.0±2.8 42.0±1.4 39.5±3.5 28.0±4.2 39
Postmenopausal 39 (34.8%) 19 8 1 4 3 2 1 0 1 0
Familial history* (Yes) 11 (9.8%) 4 5 0 0 0 0 1 0 0 1
Site diagnosed first
Primary focus 48 (42.9%) 17 22 1 - 2 - 221 1
Ovary 3 (2.6%) 1 1 --1 ---- -
Simultaneous 61 (54.5%) 28  11  9 9 1 2 --1 -
Adenocarcinoma 108 (96.4%) 46  34 10 9 4 2 2 2 2 0
Signet ring cell 18 2 13 0 3 0 0 0 0 0 0
Mucinous 79 43 21 0 5 4 2 2 2 0 0
Endometrioid 7 0 0 7 0 0 0 0 0 0 0
Serous 4 0 0 3 1 0 0 0 0 0 0
Non-adenocarcinoma 4 (3.6%) 1 0 0 0 0 0 0 0 2 1
Interval
�(months, 
mean±SD) 10.8±18.3 7.4±14.0 21.4±24.5 0.8±2.5 - 3.3±3.3 - 36.0±14.1 12.0±5.7 9.0±12.7 8
Adjuvant therapy
� 110 (98.2%) 45 34 10 8 4 2 2 2 2 1
Table 1. Patient characteristics in metastatic ovarian cancer
*, first-degree relatives with breast, gastrointestinal, or gynecologic malignancies; 
� , interval between diagnoses of primary and secondary malignan-
cies; 
� , postoperative chemotherapy±radiotherapy.
SD, standard deviation. 116 S.-J. Lee, J.-H. Bae, A.-W. Lee, et al.
operative mass detection by imaging successful if provided
any suspicion or suggestion of the ovarian metastasis or malig-
nant mass. Accordingly, the preoperative detection rate with
imaging was 75%, and it appeared to be higher for ovarian
metastases from colorectal and gynecologic origins (p=0.050).
Multilocularity was a typical pattern in ovarian metastases
from colorectal or gynecologic origins (p=0.028). A large num-
ber of metastatic ovarian cancers showed multilocular and
mixed (cystic-solid) patterns with or without ascites, suggest-
ing primary ovarian cancer.
Preoperative CA-125 concentration was measured in 80
(71.4%) patients. Thirty-two (40.0%) of those had elevated
serum CA-125 concentrations (≥35 U/mL), and the mean
values of preoperative serum CA-125, according to the pri-
mary tumor site, were not significantly different among the
Total
(n=112)
p value*
Subgroup 1
(n=46)
Subgroup 2
(n=34)
Subgroup 3
(n=11)
Subgroup 4
(n=21)
Preoperative detection rate (%) 84 (75%) 39 (84.8%) 21 (61.8%) 10 (90.9%) 14 (66.7%) 0.050
Bilaterality 61 (54.5%) 28 (60.9%) 20 (43.5%) 4 (36.4%) 13 (61.9%) 0.052
Multilocularity 79 (70.5%) 38 (82.6%) 18 (52.9%) 9 (81.8%) 14 (66.7%) 0.029
Ascites
Yes (%) 60 (53.6%) 24 (52.2%) 16 (47.1%) 8 (72.7%) 12 (57.1%) 0.502
Nature of ovarian mass 0.032
No mass (false negative) 28 (25%) 7 (15.2%) 13 (38.2%) 1 (9.1%) 7 (33.3%)
Solid 9 (8.0%) 1 (2.2%) 4 (11.8%) 2 (18.2%) 2 (9.6%)
Cystic 30 (26.8%) 18 (39.1%) 6 (17.6%) 1 (9.1%) 5 (23.8%)
Mixed (cystic-solid) 45 (40.2%) 20 (43.5%) 11 (32.4%) 7 (63.6%) 7 (33.3%)
Largest mass (cm) 9.7±5.5 10.7±5.8 10.0±5.0 9.0±6.0 7.7±4.7 0.193
(mean±SD)
Table 2. Preoperative detection of metastatic ovarian cancer 
*, p value from ANOVA and Fisher’s exact test.
SD, standard deviation; Subgroup 1, from colorectal cancer; Subgroup 2, from stomach cancer; Subgroup 3, from gynecologic cancer; Subgroup 4,
from gallbladder, appendix, breast, lung, lymphoma, and unknown origin. 
Fig. 1. Survival rates of patients with metastatic ovarian cancer
according to primary tumor origin.
Subgroup 1, from colorectal cancer; Subgroup 2, from stomach
cancer; Subgroup 3, from gynecologic cancer; Subgroup 4, from
cancers of gallbladder, appendix, breast, lung, lymphoma, and
unknown origin. 
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Subgroup 1  9 months 52.1% 38.5% 12.8% 12.8% 12.8%
(n=46) 
Subgroup 2  9 months 44.1% 29.4% 23.5% 10.5% 5.2%
(n=34)
Subgroup 3  24 months 80.0% 68.7% 68.7% 68.7% 68.7%
(n=11)
Subgroup 4  12 months 61.9% 51.6% 20.6% 20.6% 6.9%
(n=21)
Fig. 2. Survival rates for patients according to extent of cytoreduc-
tive surgery.
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subgroups (p=0.322) (Table 3).
Patient survival rates are shown in Fig. 1, 2. The survival
rate of subgroup 3 (gynecologic origin) was significantly bet-
ter than that of other subgroups (p=0.002), and there were
no significant differences in survival among subgroups 1, 2,
and 4. 
Although we initially attempted curative and optimal
cytoreduction for all patients, optimal resection was achieved
by extensive surgery in 62 (55.4%). The median patient
survival was 17 months after extensive cytoreduction and 9
months after minimal surgery. As shown in Fig. 2, exten-
sive surgery improved the survival outcome of metastatic
ovarian cancer (p=0.041).
We analyzed prognostic variables and estimated hazard
ratios for patient death with a log-rank test and Cox propor-
tional hazards model (Table 4). Metastasis from non-gyneco-
logic malignancies and minimal resection were unfavorable
prognostic factors in a univariate analysis. Ovarian metasta-
sis from gynecologic origin was a significant favorable prog-
nostic factor in multivariate analysis (p=0.004).
DISCUSSION
In the present study, metastatic ovarian cancer accounted
for 13.6% of all ovarian malignancies. The overall incidence
of metastatic ovarian cancer in the Korean population is high-
er than that in Europe and North America. Colorectal and
stomach cancer were major primary origins, and the propor-
tion of breast cancer origin was much lower in the present
study compared to data from Western countries (3-7). The
global incidence of stomach cancer is concentrated in East-
ern Asia and some South American, Southeastern European,
and African countries. Regionally, stomach cancer is the most
common cancer in Eastern Asia and the third most common
cancer in South America and Southeastern Europe. Breast
cancer is the second most common and colorectal cancer is
the third most common cancer worldwide after lung and
breast. The incidence rates of breast and colorectal cancer are
highest in developed Western countries and lowest in Africa
and Asia. However, Japan and Korea are exceptions, having
age-standardized rates similar to Europe (20). According to
the 2005 Korean Cancer Registry, stomach, breast, and col-
orectal cancer, in that order, were the most common cancers
in Korean women. The prevalence of metastatic ovarian can-
cer seems to reflect the overall incidence and ethnic variances
of primary cancer. In the present study, the mean age of pati-
ents with metastatic ovarian cancer was approximately 10 yr
lower than that of patients with primary ovarian cancer (17).
Many metastatic adenocarcinomas involving the ovary
show morphologically and clinically similar patterns. There-
fore, multidisciplinary approaches, including radiological,
serological, and pathological methods are required for diag-
nosis. A known history of a primary malignancy is useful
for diagnosis, but many cases present symptoms related to
an ovarian mass without a history of malignancy. In this study,
Number of 
measured cases
p value
� Primary tumor origin
% with elevated 
CA-125 (≥35 U/mL)
Range
(minimum-maximum)
Preoperative
value (median)
Preoperative value
(mean±SD)
Subgroup 1 (n=46) 26 34.6% (9/26) 8.0-735.0 70.33 163.3±214.8 0.322
Subgroup 2 (n=34) 24 58.3% (14/24) 3.5-11900.0 31.90 567.4±2416.5
Subgroup 3 (n=11) 11 27.3% (3/11) 4.5-780.4 124.08 228.2±287.5
Subgroup 4 (n=21) 19 31.6% (6/19) 1.6-3500.0 112.84 350.0±796.2
Total (n=112) 80 40.0% (32/80) 1.6-11900.0 52.09 337.8±1377.4
Table 3. Preoperative serum concentration of CA-125 in metastatic ovarian cancer* 
SD, standard deviation; Subgroup 1, from colorectal cancer; Subgroup 2, from stomach cancer; Subgroup 3, from gynecologic cancer; Subgroup 4,
from cancer of gallbladder, appendix, breast, lung, lymphoma, and unknown origin. 
*, measured in 80 patients; 
� , p values from Kruskal-Wallis test.
HR (95% CI) p value
Prognostic variables
Univariate analysis
HR (95% CI) p value
Multivariate analysis
Age 0.987 (0.966-1.008) 0.227
Inter-diagnostic interval  0.999 (0.988-1.010) 0.846
Lesion size 0.983 (0.946-1.023) 0.402
Ascites 0.929 (0.601-1.437) 0.742
Metastasis from gynecologic malignancy 0.195 (0.061-0.619) 0.006 0.190 (0.058-0.592) 0.004
Extensive cytoreductive surgery 0.635 (0.405-0.996) 0.048 0.952 (0.710-1.272) 0.255
Table 4. Hazard ratio for death
Statistically significant findings in bold.
HR, hazard ratio; CI, confidence interval.118 S.-J. Lee, J.-H. Bae, A.-W. Lee, et al.
more than half of the metastatic ovarian cancers were diag-
nosed simultaneously with primary malignancies, and the
proportion of bilateral ovarian involvement was 54.5%. There
were no significant differences in bilaterality and the largest
mass size of metastatic ovarian malignancies based on the
primary tumor site.
Preoperative detection of metastatic ovarian tumor was
made in 75% of the present cases. As described in previous
radiology studies, the nature of an ovarian mass and lesion
size may be useful for diagnosis (8, 10). In the present study,
multilocularity was a more frequent pattern in metastatic
ovarian tumors from colorectal or gynecologic malignancies.
However, differential diagnosis of ovarian masses based sole-
ly on radiology carries the risk of misinterpretation and may
have adverse consequences for patients. As shown in Table 3,
serum concentration of CA-125 was not useful for detection.
In addition to morphological and clinical information, fur-
ther evaluation, such as immunostains for cytokeratins 7 and
20 and other histopathological markers may be useful for dif-
ferential diagnosis of metastatic ovarian cancers (2, 18, 19).
The multivariate analysis to evaluate prognostic factors for
metastatic ovarian cancer showed that the primary tumor site
was the most important factor. Ovarian metastases of gyne-
cologic origin had a much better prognosis than those from
non-gynecologic organs. Compared with metastases from non-
gynecologic malignancy, carcinomatosis of advanced gyne-
cologic cancer is relatively confined to the intraabdominal
cavity without distant metastasis and shows superficial spread-
ing patterns (21, 22). From these reasons, the metastatic ovar-
ian cancer from gynecologic malignancy might show longer
survival than those from non-gynecologic organs. Metastatic
cancer of colorectal origin showed favorable prognosis among
other non-gynecologic cancers, but there was no significant
prognostic difference in non-gynecologic metastatic cancers
based on the primary tumor site. Extensive resection may
prolong survival. As described in previous studies, surgical
resection should be considered as indicated by a patient’s con-
dition (5, 12-15).
The present study has some limits. First, our sample was
not representative of the general population of Korean wo-
men. Second, information regarding diagnosis and treatment
outcome was limited due to the study’s retrospective design.
However, it is difficult to execute a well-designed, prospec-
tive trial on this topic. Continued follow-up and large-scale
data collection will provide accurate, long-term information
about metastatic ovarian cancer and the benefits of a secondary
tumor screening program. In addition to studies that evalu-
ate outcomes of surgical resection, studies of chemotherapy
outcomes are necessary.
In conclusion, the incidence of metastatic ovarian cancer
appears to be higher in Korean women compared to the inci-
dence in Western countries. Colorectal and stomach cancer
were the major primary origins of metastatic ovarian tumors.
The differential diagnosis of metastatic ovarian cancer is prob-
lematic, and multiple diagnostic approaches are required to
enhance detection accuracy. Surgical intervention may be
appropriate in some cases, and the extent and type of surgery
should be decided on a case-to-case basis.
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